Table 1.
Epidemiological, clinical, and laboratory findings of 53 patients with disseminated sporotrichosis at INI/FIOCRUZ.
| Group 1 (n = 17) | Group 2 (n = 36) | |
|---|---|---|
| Mean age in years (range) | 35.3 (20–57) | 43 (16–72) |
| Male—n (%) | 15 (88.2%) | 29 (80.6%) |
| Non-white skin color—n (%) | 16 (94.1%) | 24 (66.7%) |
| Close contact with cats—n (%) | 12 (70.6 %) | 28 (77.8%) |
| Immunosuppression—n (%) | ||
| HIV infection | 15 (88.2%) | 27 (75%) |
| Alcoholism | 1 (5.9%) | 2 (5.6%) |
| Chronic steroid use | 1 (5.9%) | 4 (11.1%) |
| None of the above | - | 3 (8.3%) |
| Mean duration of signs/symptoms until lumbar puncture in months (range) | 6.9 (1–20) | 7.4 (1–67) |
| Mean CSF cells/mm3 (range) | 71.5 (3–363) | 2 (0–5) |
| Mean CSF glucose mg/dL (range) | 39.6 (14–65) | 59.1 (27–148) |
| Mean CSF protein mg/dL (range) | 117 (32.3–307) | 50.1 (13–181) |
| Mean duration of first hospital admission in days (range) | 45.1 (10–120) | 28.2 (1–86) |
| ICU admission—n (%) | 6 (35.3%) | 0 |
| Death—n (%) | 11 (64.7%) | 10 (27.8%) |
Group 1: patients with symptoms and signs of meningitis; group 2: patients with no neurological symptoms and CSF cell count ≤ 5 cells/mm³. HIV: human immunodeficiency virus. CSF: cerebrospinal fluid. ICU: intensive care unit.